Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 244

Posts Tagged ‘hematology’

62° Meeting annuale della American Society of Hematology (ASH)

Posted by fidest press agency su mercoledì, 9 dicembre 2020

Stockley Park (Regno Unito) Kite, società del gruppo Gilead, ha annunciato i dati di follow-up a quattro anni dello studio registrativo ZUMA-1 condotto con axicabtagene ciloleucel in pazienti adulti con linfoma a grandi cellule B (LBCL, large B cell lymphoma) recidivante/refrattario. Tra i pazienti trattati con axicabtagene ciloleucel (analisi intent-to-treat modificata, n = 101), con un follow-up minimo di quattro anni dopo una singola infusione di axicabtagene ciloleucel (follow-up mediano di 51,1 mesi), la stima col metodo Kaplan-Meier del tasso di sopravvivenza globale (OS, overall survival) a quattro anni è stata del 44%. I dati sono stati presentati oggi al 62° meeting ed esposizione annuale della American Society of Hematology (ASH) (abstract #1187).1 Tra i 111 pazienti arruolati nelle coorti dello studio clinico di fase II ZUMA-1, axicabtagene ciloleucel è stato somministrato a 101 soggetti con LBCL recidivante/refrattario, e il tempo mediano dalla leucaferesi alla risposta completa (CR, complete response) è stato inferiore a due mesi. Non sono state segnalate neoplasie secondarie correlate ad axicabtagene ciloleucel.

Posted in Medicina/Medicine/Health/Science | Contrassegnato da tag: , , | Leave a Comment »

Global Hematology Diagnostic Devices and Equipment Market Report 2020

Posted by fidest press agency su domenica, 15 dicembre 2019

The “Hematology Diagnostic Devices And Equipment Global Market Report 2020” report has been added to ResearchAndMarkets.com’s offering.The global hematology diagnostic devices and equipment market was valued at about $1.9 billion in 2018 and is expected to grow to $2.35 billion at a CAGR of 5.5% through 2022.The hematology diagnostics devices and equipment market consists of sales of hematology diagnostics devices and related services. Hematology diagnostics instruments are used to diagnose diseases related to blood, vascular systems, bone marrow, auto immune disorders and hemostasis.These devices include automated cell counters, red cell indices devices, micro sedimentation centrifuges, or blood volume measuring devices, occult blood tests, platelet aggregometers, erythrocyte sedimentation rate tests, red blood cell enzyme assay kits, glutathione reductase assays and hematology reagents.Hematology diagnostic devices are driven by the increase in the prevalence of blood disorders. Hematology diagnostic devices are widely used in order to identify the type of blood disorder. A blood disorder is a condition which impacts the count of blood cells like red blood cells, white blood cells, platelets, etc. Blood disorders affect millions of people each year across the world irrespective of age, race, and sex. E.g.. As per the World Health Organization, Hemoglobin disorder affects 75% of the total births globally and the prevalence of Anemia in men is 12.7%.Product recall is one of the major problems that the companies are facing. Product recall is the process of returning faulty devices due to the errors in the manufacturing of the devices. Because of the faulty devices, tests conducted in diagnostic centers may get affected. For example, In 2018, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes because they are affecting the test due to the chemical interference of test tubes with the blood samples. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA). Such product recalls can negatively affect market growth.Companies in the hematology diagnostic devices are increasingly investing on the automation technology. Automation technology advancements are driving the demand for hematology analyzers and this automation will reduce the errors caused by manual practices in diagnostic centers. For example, Sysmex acquired a CLIA waiver for a newly automated hematology analyzer; by selling this product, Sysmex makes it possible for clinical facilities to perform hematology testing without manual errors.The hematology diagnostic devices market has a potential to grow rapidly, but stringent regulation policies are restricting its growth. The FDA currently regulates class I, class II, and class III hematology devices. Class I hemostasis devices are exempt from the premarket notification requirements and only used for general control. Regulations for class II devices are exempt from the premarket notification requirements and they can be used for special controls. Class III is the most stringent category as it requires premarket approval (PMA).

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

61st American Society of Hematology Annual Meeting

Posted by fidest press agency su domenica, 17 novembre 2019

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced that ALX148 clinical results have been selected for presentation at the 61st ASH Annual Meeting & Exposition, December 7 – 10, 2019, Orange County Convention Center, Orlando, FL.“This year’s ASH meeting will be an opportunity to provide important clinical updates on our CD47 program in hematologic malignancies,” said Sophia Randolph M.D., Ph.D., Chief Medical Officer of ALX Oncology. “We are excited to share the first clinical efficacy data from the combination of ALX148 with rituximab, showing that ALX148 maximizes clinical activity with a best-in-class safety profile. We are committed to further development of this agent with the potential to transform standards-of-care for patients with cancer.”

Posted in Estero/world news, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

MJH Associates Announces Partnership with Hematology-Oncology Associates of Central New York

Posted by fidest press agency su mercoledì, 31 luglio 2019

MJH Associates‚ Inc., a full-service multimedia medical media company, announces a Strategic Alliance Partnership (SAP) between Hematology-Oncology Associates of Central New York (HOA) and three of its premiere brands, Targeted Oncology™, The American Journal of Managed Care® (AJMC®) and Pharmacy Times®.
HOA is a multispecialty, multilocation, highly integrated and comprehensive oncology practice that is also a member of the Community Oncology Alliance. In addition to its robust clinical practice, HOA leads local advocacy for access, care integration and value based-care. HOA is the only oncology practice in Central New York certified for quality by the American Society of Clinical Oncology (ASCO)’s Quality Oncology Practice Initiative. HOA participates as one of the National Cancer Institute’s clinical research partners and runs several patient-focused programs in survivorship and patient education outreach for cancer and metastatic disease.HOA offers CyberKnife; high-tech radiation therapy; diagnostic imaging services; lab, infusion and dispensing pharmacy services; nutritional consultations; cancer rehabilitation/physical therapy; and palliative care, survivorship and social work services to thousands of patients. HOA has certifications with the American College of Radiology and ASCO, and it has a dispensing pharmacy certified by the Accreditation Commission for Health Care as a Specialty Pharmacy with a Distinction in Oncology.The MJH SAP program is constantly building a community of health plans, advocacy groups, medical associations and medical institutions to foster collaboration and an open exchange of information for the ultimate benefit of patients and their families and improving patient care. As part of this joint effort, Targeted Oncology™, AJMC® and Pharmacy Times® will work with HOA to share exclusive digital content and bring clinical educational opportunities to its community through case-based regional programming.

Posted in Estero/world news, Uncategorized | Contrassegnato da tag: , , | Leave a Comment »

Takeda to Demonstrate Global Leadership in Hematology at ISTH 2019

Posted by fidest press agency su giovedì, 4 luglio 2019

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”), the global biotechnology leader in rare diseases, will present research covering a broad range of rare bleeding disorders at the 27th Annual International Society on Thrombosis and Haemostasis Congress (ISTH), July 6-10, 2019 in Melbourne, Australia. Showcased in 10 oral presentations and 38 poster presentations, these data underscore Takeda’s pursuit of treatment innovation to achieve optimized and personalized patient care in hematology.
“At Takeda, we are proud of the hematology heritage Shire, Baxalta and Baxter built over 70 years and we plan on expanding on it through continued research and innovation, in pursuit of a world without bleeds,” said Dr. med. Wolfhard Erdlenbruch, Vice President Head of Global Medical Affairs Hematology, Takeda. “We look forward to presenting new data from PROPEL and important updates from our gene therapy and leading factor pipeline at ISTH 2019, showcasing our continued development and commitment in this area.”
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines.Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

European Hematology Association 2019 Annual Meeting

Posted by fidest press agency su martedì, 18 giugno 2019

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused on developing and commercializing medicines seeking to improve the survival and quality of life of cancer patients, today announced that two posters highlighting clinical data for COPIKTRA™ (duvelisib) in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) were presented at the European Hematology Association (EHA) 2019 Annual Meeting which took place June 13-16, 2019, in Amsterdam. One poster describes results from a post-hoc analysis evaluating the effect of COPIKTRA on lymphocytosis in patients with relapsed or refractory CLL/SLL from the Phase 3 DUO study, including patients with high-risk factors. The other poster describes dose modification data from patients with relapsed or refractory CLL/SLL in the DUO study. COPIKTRA, a targeted oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, received approval as monotherapy from the U.S. Food and Drug Administration (FDA) in September 2018 for the treatment of patients with relapsed or refractory CLL/SLL after at least two prior therapies.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Spectrum Pharmaceuticals Announces Leadership Changes

Posted by fidest press agency su martedì, 19 dicembre 2017

Natali a New York (2)New York. Spectrum Pharmaceuticals, Inc. (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that its Board of Directors has terminated Rajesh C. Shrotriya, MD without cause from his position as Chief Executive Officer, and announced leadership changes under which Joseph W. Turgeon, the current President and Chief Operating Officer, has been named President and Chief Executive Officer and elected to the Board of Directors, and current Director Stuart M. Krassner, ScD, PsyD, has been named Chairman of the Board. In addition, Thomas J. Riga, who currently serves as Executive Vice President, Chief Commercial Officer and Head of Business Development, has been named Chief Operating Officer. These changes are effective immediately.Mr. Turgeon brings more than 30 years of experience in the pharmaceutical industry, including various executive leadership roles at Amgen Inc. He had served as Spectrum’s President and Chief Operating Officer since April 2014, and had previously served as the Company’s Senior Vice President and Chief Commercial Officer from October 2012 to April 2014. Prior to joining Spectrum, Mr. Turgeon spent 22 years at Amgen Inc. as Vice President of Sales.
Mr. Riga brings over 15 years of pharmaceutical sales and management experience in various positions at Amgen, Eli Lilly and Dendreon, including as Vice President of Sales at Dendreon. He had served as Spectrum’s Executive Vice President, Chief Commercial Officer and Head of Business Development since June 2017, and previously served as Spectrum’s Senior Vice President and Chief Commercial Officer from August 2014 to June 2017, and Vice President, Corporate Accounts from July 2013 to August 2014.
Dr. Krassner has served as a director of Spectrum since December 2004, and was previously a member of Spectrum’s Scientific Advisory Board from 1996 to 2001. Dr. Krassner’s career spans nearly four decades of experience in positions of increasing responsibility at the University of California at Irvine, most recently as Professor of Developmental and Cell Biology at the School of Biological Sciences. Dr. Krassner is Professor Emeritus, University of California, Irvine and has also been retained by pharmaceutical, medical device and other companies, including Allergan Pharmaceuticals, Lasermed Corporation, Automated Microbiology Systems, and In Vitro International, among others, to provide scientific and regulatory advisory services, including FDA compliance. He is a past member of the American Academy for the Advancement of Sciences, and the American Society of Tropical Medicine and Hygiene, among others.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »